"ESMO Abstract Leak Unveils Exciting NSCLC Therapies and Neoadjuvant Nivolumab Advancements"
Originally Published 2 years ago — by BioSpace
The European Society for Medical Oncology (ESMO) Congress 2023 has experienced an embargo breach, revealing promising therapies for non-small cell lung cancer (NSCLC). Bristol Myers Squibb's Opdivo demonstrated positive results in two Phase III studies, showing a reduction in disease recurrence and improved survival rates. Mirati's adagrasib, when combined with Keytruda, showed strong first-line promise in NSCLC patients. BeiGene's tislelizumab, in combination with chemotherapy, achieved a major pathological response in a Phase III trial. Johnson & Johnson's Rybrevant-lazertinib combination demonstrated potential as a new standard of care for EGFR-mutated NSCLC. These findings will be presented at the ESMO Congress in October.
